Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.40 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.40 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 6/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192466 | 1.00 | NAE1 (0.40) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL192468 | 1.00 | NAE1 (0.40) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL191523 | 0.86 | NAE1 (0.54) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL191521 | 0.86 | NAE1 (0.54) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL191522 | 0.86 | NAE1 (0.54) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL10186225 | 0.86 | ACACB (0.38) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL192873 | 0.86 | NAE1 (0.38) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL192872 | 0.86 | NAE1 (0.38) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL192874 | 0.86 | NAE1 (0.38) | NAE1CA2GRK5CSNK1A1UBA6 | |
| SCHEMBL18837015 | 0.81 | NAE1 (0.63) | NAE1CA2GRK5CSNK1A1UBA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2402334-B1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARM INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| EP-1989206-B1 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8207177-B2 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2402334-A1 | Inhibitors of E1 Activating Enzymes | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258977-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
| US-20120258927-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | NAE1 75/4885CA2 3434/4885GRK5 2562/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | NAE1 41/4885CA2 3826/4885GRK5 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.